Ultragenyx Pharmaceutical (RARE) Set to Announce Earnings on Thursday

Ultragenyx Pharmaceutical (NASDAQ:RARE) will be issuing its quarterly earnings data after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of ($1.73) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($1.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.65) by $0.13. Ultragenyx Pharmaceutical had a negative net margin of 139.70% and a negative return on equity of 369.54%. The firm had revenue of $127.39 million for the quarter, compared to analyst estimates of $119.38 million. During the same period last year, the firm earned ($2.16) earnings per share. The business’s quarterly revenue was up 23.3% compared to the same quarter last year. On average, analysts expect Ultragenyx Pharmaceutical to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Ultragenyx Pharmaceutical Trading Down 0.8 %

Shares of RARE traded down $0.34 on Tuesday, reaching $43.68. The company’s stock had a trading volume of 95,494 shares, compared to its average volume of 745,294. Ultragenyx Pharmaceutical has a twelve month low of $31.52 and a twelve month high of $54.98. The firm has a fifty day moving average of $47.70 and a 200-day moving average of $43.99.

Insider Activity at Ultragenyx Pharmaceutical

In other news, insider John Richard Pinion sold 4,173 shares of Ultragenyx Pharmaceutical stock in a transaction on Friday, March 1st. The stock was sold at an average price of $53.76, for a total value of $224,340.48. Following the completion of the transaction, the insider now directly owns 89,268 shares in the company, valued at $4,799,047.68. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Ultragenyx Pharmaceutical news, insider John Richard Pinion sold 4,173 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $53.76, for a total value of $224,340.48. Following the completion of the transaction, the insider now owns 89,268 shares in the company, valued at approximately $4,799,047.68. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Thomas Richard Kassberg sold 11,509 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $49.93, for a total transaction of $574,644.37. Following the completion of the transaction, the executive vice president now owns 252,823 shares of the company’s stock, valued at $12,623,452.39. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 32,116 shares of company stock worth $1,645,983. 6.80% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on RARE. Royal Bank of Canada initiated coverage on Ultragenyx Pharmaceutical in a report on Monday, April 22nd. They issued an “outperform” rating and a $77.00 target price on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, March 18th. Robert W. Baird increased their target price on shares of Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the company an “outperform” rating in a report on Tuesday, January 30th. TD Cowen upped their price objective on shares of Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Finally, Canaccord Genuity Group increased their price objective on shares of Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the company a “buy” rating in a research note on Wednesday, February 21st. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $88.08.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.